% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Laurent:296013,
      author       = {P.-A. Laurent and F. André and A. Bobard and D. Deandreis
                      and S. Demaria and S. Depil and S. Eichmüller$^*$ and C.
                      Fernandez-Palomo and F. Foijer and L. Galluzzi and J. Galon
                      and M. Guckenberger and K. J. Harrington and F. G. Herrera
                      and P. Huber$^*$ and A. Italiano and S. D. Karam and G.
                      Kroemer and P. Lambin and C. Leuschner and A. Mantovani and
                      E. Meylan and M. Mondini and M. J. Pittet and J.-P. Pouget
                      and J. Remon and C. S. Sørensen and C. Sotiriou and C.
                      Vanpouille-Box and R. R. Weichselbaum and J. W. Welsh and L.
                      Zitvogel and S. C. Formenti and E. Deutsch},
      title        = {{P}ushing the boundaries of radiotherapy-immunotherapy
                      combinations: highlights from the 7th immunorad conference.},
      journal      = {OncoImmunology},
      volume       = {14},
      number       = {1},
      issn         = {2162-4011},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Franics},
      reportid     = {DKFZ-2024-02756},
      pages        = {2432726},
      year         = {2025},
      abstract     = {Over the last decade, the annual Immunorad Conference, held
                      under the joint auspicies of Gustave Roussy (Villejuif,
                      France) and the Weill Cornell Medical College (New-York,
                      USA) has aimed at exploring the latest advancements in the
                      fields of tumor immunology and radiotherapy-immunotherapy
                      combinations for the treatment of cancer. Gathering medical
                      oncologists, radiation oncologists, physicians and
                      researchers with esteemed expertise in these fields, the
                      Immunorad Conference bridges the gap between preclinical
                      outcomes and clinical opportunities. Thus, it paves a
                      promising way toward optimizing radiotherapy-immunotherapy
                      combinations and, from a broader perspective, improving
                      therapeutic strategies for patients with cancer. Herein, we
                      report on the topics developed by key-opinion leaders during
                      the 7th Immunorad Conference held in Paris-Les Cordeliers
                      (France) from September 27th to 29th 2023, and set the stage
                      for the 8th edition of Immunorad which will be held at Weill
                      Cornell Medical College (New-York, USA) in October 2024.},
      keywords     = {Humans / Neoplasms: immunology / Neoplasms: radiotherapy /
                      Neoplasms: therapy / Immunotherapy: methods / Combined
                      Modality Therapy / Radiotherapy: methods / Cancer (Other) /
                      FLASH radiotherapy (Other) / T cells (Other) / immune
                      checkpoint (Other) / immunorad (Other) / immunotherapy
                      (Other) / low-dose radiotherapy (Other) / lymph-node sparing
                      (Other) / radiotherapy (Other) / tumor-associated
                      macrophages (Other)},
      cin          = {D210 / E055},
      ddc          = {610},
      cid          = {I:(DE-He78)D210-20160331 / I:(DE-He78)E055-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39696783},
      pmc          = {pmc:PMC11660406},
      doi          = {10.1080/2162402X.2024.2432726},
      url          = {https://inrepo02.dkfz.de/record/296013},
}